Search - tctmd.com

Displaying 101 - 120 of 181

Sort: Relevancy | Date

News Daily News

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Michael O'Riordan

June 05, 2017

News Daily News

Lowering of Systolic BP Beyond Current Targets Gets Boost in New Analysis

Michael O'Riordan

May 31, 2017

News Daily News

Post-MI High-Intensity Statin Use Has Doubled in Recent Years

Michael O'Riordan

May 30, 2017

News Daily News

Statins Provide No Benefit in Older Adults Without CVD: ALLHAT Analysis

Michael O'Riordan

May 29, 2017

News Conference News EuroPCR 2017

Embolic Protection During TAVR Reduces Volume of Cerebral Lesions, but Clinical Benefit Not Evident: Meta-analysis

Michael O'Riordan

May 26, 2017

News Conference News EuroPCR 2017

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

Michael O'Riordan

May 24, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Conference News EuroPCR 2017

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

Michael O'Riordan

May 19, 2017

News Conference News EuroPCR 2017

Transradial PCI in ACS Reduces Risk of Acute Kidney Injury

Michael O'Riordan

May 18, 2017

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Daily News

HF Survival Rates Worse Than Those of Common Cancers, Including Bladder and Breast Cancer

Michael O'Riordan

May 10, 2017

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

News Daily News

‘Sizeable’ Segment of Public, Even When at High CVD Risk, Feels No Need to Improve Health

Michael O'Riordan

May 04, 2017

News Daily News

High-Volume Surgeons More Likely to Perform Durable Mitral Valve Repairs, Have Better Outcomes

Michael O'Riordan

May 04, 2017

News Daily News

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Michael O'Riordan

April 27, 2017

Advertisement

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Lowering of Systolic BP Beyond Current Targets Gets Boost in New Analysis

Post-MI High-Intensity Statin Use Has Doubled in Recent Years

Statins Provide No Benefit in Older Adults Without CVD: ALLHAT Analysis

Embolic Protection During TAVR Reduces Volume of Cerebral Lesions, but Clinical Benefit Not Evident: Meta-analysis

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

Transradial PCI in ACS Reduces Risk of Acute Kidney Injury

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

HF Survival Rates Worse Than Those of Common Cancers, Including Bladder and Breast Cancer

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

‘Sizeable’ Segment of Public, Even When at High CVD Risk, Feels No Need to Improve Health

High-Volume Surgeons More Likely to Perform Durable Mitral Valve Repairs, Have Better Outcomes

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content